

SUPPLEMENTAL FIGURES AND LEGENDS

Supplemental Figure 1

Supp. Fig. 1. CD9 deficiency does not affect surface expression of several surface markers. Immature and LPS-matured CD11c⁺ WT and CD9 KO GM-CSF-dependent BMDCs (thereafter called MoDCs) were stained for with different antibodies against (A) CCR7, (B) ICAM-1, (C) CD49d, (H)

CD86, (**I**) CD80, and (**J**) CD40, and analyzed by flow cytometry. Splenic WT and CD9 KO DCs were stained for with different antibodies against (**D**) ICAM-1, (**E**) CD49d, (**F**) CD11b, and (**G**) CD11c and B220 to differentiate plasmacytoid and conventional DCs. (A-C; H-J) Data are mean-fold induction \pm SEM from two independent experiments analyzed by one-way ANOVA with Tukey's post-hoc multiple comparison test, and (D-G) means \pm SEM of two independent experiments analyzed by Student *t*-test.



Supplemental Figure 2

Supp. Fig. 2. CD9 deficiency does not modify the expression levels of different markers of intracellular vesicles. (A-C) Immature or LPS-matured WT and CD9 KO MoDCs were plated onto PLL-coated coverslips, fixed, permeabilized, stained for with antibodies against MHC-II and (A) EEA1, (B) HGS/HRS, or (C) CD63, and analyzed by confocal microscopy. Graphs show the quantification of (A) EEA1-MHC-II, (B) HGS/HRS-MHC-II, or (C) CD63-MHC-II co-localization performed in 3D stack confocal microscopy images, and quantified by Mander's coefficient. Data are means ± SEM of three independent experiments (A, at least n=100 immature and 40 mature cells; B, at least n=85 immature and mature cells; C, at least n=25 immature and 20 mature cells) analyzed by one-way ANOVA with Tukey's post-hoc multiple comparison test. (D-G) Immature and LPS-matured CD11c⁺MHC-II⁺ WT and CD9 KO

DCs were fixed, permeabilized, stained for with different antibodies against (**D**) EEA1, (**E**) HGS/HRS, (**F**) CD63, (**G**) LAMP1, and analyzed by flow cytometry. Graphs show the mean-fold induction \pm SEM of three independent experiments analyzed by one-way ANOVA with Tukey's post-hoc multiple comparison test. (**H**) Immature and LPS-matured WT and CD9 KO DCs were loaded with different concentrations of Lysotracker Red for 30min at 37°C, washed, stained for with antibodies against CD11c and MHC-II, and analyzed by flow cytometry. Data are mean-fold induction \pm SEM from three independent experiments analyzed by one-way ANOVA with Tukey's post-hoc multiple comparison test.



Supplemental Figure 3

Supp. Fig. 3. Antigen proteolytic processing is not affected in CD9 KO MoDCs. (A-B) Immature WT and CD9 KO MoDCs were treated with 25mM of NH_4Cl or with the vehicle for 1h at 37°C, and (A) surface and (B) total MHC-II expression in $CD11c^+$ cells was analyzed by flow cytometry. Data are mean-fold induction \pm SEM from three independent experiments analyzed by one-way ANOVA with Tukey's post-hoc multiple comparison test. (C) Immature WT and CD9 KO DCs were incubated for

different times with DQ-OVA, washed and the percentage of DQ-OVA⁺ cells was analyzed by flow cytometry. Data are means \pm SEM from four independent experiments analyzed by two-way ANOVA with Bonferroni's post-hoc multiple comparison test. (**D-E**) LPS-matured WT and CD9 KO DCs were analyzed as in A-B. Data are mean-fold induction \pm SEM from three independent experiments analyzed by one-way ANOVA with Tukey's post-hoc multiple comparison test.



Supplemental Figure 4

Supp. Fig. 4. CD9 deficiency does not affect MHC-II ubiquitination. (A-B) Immature and LPSmatured WT and CD9 KO MoDCs were treated with 10μ M of MG132 or with the vehicle for 4h at 37°C, and (A) surface and (B) total MHC-II expression in CD11c⁺ cells were analyzed by flow cytometry. Data are mean-fold induction ± SEM from three independent experiments analyzed by one-way ANOVA with Tukey's post-hoc multiple comparison test. (C) Cell lysates from immature and LPS-matured WT and CD9 KO MoDCs were immunoprecipitated with an anti-MHC-II antibody (M5/114), and ubiquitinated proteins detected after membrane incubation with anti-ubiquitin antibodies. Membranes were re-probed with MHC-II antibody for loading measurement. In the control lane the beads were incubated only with cell lysates from WT DCs. The blots shown are from a representative experiment out of three. Graph shows the mean-fold induction \pm SEM from three independent experiments analyzed by one-way ANOVA with Tukey's post-hoc multiple comparison test. (**D**) Total mRNA was extracted from immature WT and CD9 KO DCs pellets. The amount of MARCH-I mRNA was quantified by RT-qPCR relative to β -actin and YHAWZ controls. Data are mean-fold induction \pm SEM from two independent experiments analyzed by Student *t*-test.